Table 1.
Patient characteristics at baseline
| Characteristics | Value |
|---|---|
| Age (years) | |
| Median (range) | 66 (45–85) |
| Sex | |
| Male/female | 9/20 |
| ECOG performance status | |
| 0/1/2 | 18/10/1 |
| Disease stage | |
| IIIB/IV/Rec. | 2/25/2 |
| Histology | |
| Adenocarcinoma/other | 29/0 |
| EGFR mutation status | |
| Deletion in exon 19/L858R in exon 21/other | 11/14/4 |
| Line of afatinib | |
| First/second/third or more | 25/1/3 |
| Prior EGFR-TKI use | |
| Gefitinib/erlotinib | 4/1 |
| Prior cytotoxic agents use | |
| Platinum-doublet/single agent | 2/2 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; Rec., postoperative recurrence; TKI, tyrosine-kinase inhibitor.